83 related articles for article (PubMed ID: 28133768)
1. Inhibition of CYP2D6 with low dose (5 mg) paroxetine in patients with high 10-hydroxynortriptyline serum levels - a review of routine practice.
Jessurun N; van Puijenbroek EP; Otten LS; Mikes O; Vermeulen Windsant A; van Marum RJ; Grootens K; Derijks HJ
Br J Clin Pharmacol; 2017 May; 83(5):1149-1151. PubMed ID: 28133768
[No Abstract] [Full Text] [Related]
2. Inhibition of CYP2D6 with low dose (5 mg) paroxetine in patients with high 10-hydroxynortriptyline serum levels-A prospective pharmacokinetic study.
Jessurun NT; Vermeulen Windsant A; Mikes O; van Puijenbroek EP; van Marum RJ; Grootens K; Derijks HJ
Br J Clin Pharmacol; 2021 Mar; 87(3):1529-1532. PubMed ID: 32621544
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of atomoxetine serum levels by co-administration of paroxetine.
Paulzen M; Clement HW; Gründer G
Int J Neuropsychopharmacol; 2008 Mar; 11(2):289-91. PubMed ID: 18215333
[No Abstract] [Full Text] [Related]
5. Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN-812 (Viloxazine Extended-Release) Pharmacokinetics in Healthy Adults.
Wang Z; Kosheleff AR; Adeojo LW; Odebo O; Adewole T; Qin P; Maletic V; Schwabe S; Nasser A
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1365-1374. PubMed ID: 33943033
[TBL] [Abstract][Full Text] [Related]
6. Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients.
Solai LK; Pollock BG; Mulsant BH; Frye RF; Miller MD; Sweet RA; Kirshner M; Sorisio D; Begley A; Reynolds CF
J Clin Psychopharmacol; 2002 Oct; 22(5):481-6. PubMed ID: 12352271
[TBL] [Abstract][Full Text] [Related]
7. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers.
Ruiz-Garcia A; Giri N; LaBadie RR; Ni G; Boutros T; Richie N; Kocinsky HS; Checchio TM; Bello CL
J Clin Pharmacol; 2014 May; 54(5):555-62. PubMed ID: 24293056
[TBL] [Abstract][Full Text] [Related]
8. Altering metabolic profiles of drugs by precision deuteration: reducing mechanism-based inhibition of CYP2D6 by paroxetine.
Uttamsingh V; Gallegos R; Liu JF; Harbeson SL; Bridson GW; Cheng C; Wells DS; Graham PB; Zelle R; Tung R
J Pharmacol Exp Ther; 2015 Jul; 354(1):43-54. PubMed ID: 25943764
[TBL] [Abstract][Full Text] [Related]
9. Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions.
Storelli F; Matthey A; Lenglet S; Thomas A; Desmeules J; Daali Y
Clin Pharmacol Ther; 2018 Jul; 104(1):148-157. PubMed ID: 28940476
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of nortriptyline and 10-hydroxynortriptyline and treatment-related electrocardiographic changes in the elderly depressed.
McCue RE; Georgotas A; Nagachandran N; Abdul Basir M; Go EA; Suckow RF; Cooper TB
J Psychiatr Res; 1989; 23(1):73-9. PubMed ID: 2754630
[TBL] [Abstract][Full Text] [Related]
11. Plasma 10-hydroxynortriptyline and therapeutic response in geriatric depression.
Young RC; Alexopoulos GS; Shindledecker R; Dhar AK; Kutt H
Neuropsychopharmacology; 1988 Sep; 1(3):213-5. PubMed ID: 3251501
[TBL] [Abstract][Full Text] [Related]
12. Plasma 10-hydroxynortriptyline and ECG changes in elderly depressed patients.
Young RC; Alexopoulos GS; Shamoian CA; Kent E; Dhar AK; Kutt H
Am J Psychiatry; 1985 Jul; 142(7):866-8. PubMed ID: 4014510
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interaction between nortriptyline and terbinafine.
Van Der Kuy PH; Van Den Heuvel HA; Kempen RW; Vanmolkot LM
Ann Pharmacother; 2002 Nov; 36(11):1712-4. PubMed ID: 12398564
[TBL] [Abstract][Full Text] [Related]
14. Development and evaluation of a physiologically based pharmacokinetic model to predict carvedilol-paroxetine metabolic drug-drug interaction in healthy adults and its extrapolation to virtual chronic heart failure patients for dose optimization.
Rasool MF; Läer S
Expert Opin Drug Metab Toxicol; 2021 Jun; 17(6):717-724. PubMed ID: 33910429
[No Abstract] [Full Text] [Related]
15. Dextrometorphan-Paroxetine, But Not Dronabinol, Effective for Treatment-Resistant Aggression and Agitation in an Elderly Patient With Lewy Body Dementia.
Wilhelm R; Ahl B; Anghelescu IG
J Clin Psychopharmacol; 2017 Dec; 37(6):745-747. PubMed ID: 29035934
[No Abstract] [Full Text] [Related]
16. Study of pharmacokinetic interaction of paroxetine and roxithromycin on bencycloquidium bromide in healthy subjects.
Agbokponto JE; Luo Z; Liu R; Liu Z; Liang M; Ding L
Eur J Pharm Sci; 2015 Mar; 69():37-43. PubMed ID: 25559065
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer and antidepressant use.
Andrade C
J Clin Psychiatry; 2012 Sep; 73(9):e1156-7. PubMed ID: 23059156
[No Abstract] [Full Text] [Related]
18. Genotype-sensitive reversible and time-dependent CYP2D6 inhibition in human liver microsomes.
Storelli F; Desmeules J; Daali Y
Basic Clin Pharmacol Toxicol; 2019 Feb; 124(2):170-180. PubMed ID: 30192434
[TBL] [Abstract][Full Text] [Related]
19. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.
Bertelsen KM; Venkatakrishnan K; Von Moltke LL; Obach RS; Greenblatt DJ
Drug Metab Dispos; 2003 Mar; 31(3):289-93. PubMed ID: 12584155
[TBL] [Abstract][Full Text] [Related]
20. Genetic differences in cytochrome P450 enzymes and antidepressant treatment response.
Hodgson K; Tansey K; Dernovsek MZ; Hauser J; Henigsberg N; Maier W; Mors O; Placentino A; Rietschel M; Souery D; Smith R; Craig IW; Farmer AE; Aitchison KJ; Belsey S; Davis OS; Uher R; McGuffin P
J Psychopharmacol; 2014 Feb; 28(2):133-41. PubMed ID: 24257813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
